The Pfizer Independent Medical Education (IME) Grant Program is accepting proposals for educational symposia addressing atopic dermatitis (AD) and alopecia areata (AA). This competitive grant opportunity aims to support educational initiatives at major U.S. dermatology congresses, focusing on knowledge and practice gaps related to the diagnosis, treatment, and overall management of these conditions. Applications are due by December 5, 2024, with decisions anticipated by December 13, 2024. Selected projects can start in January 2025 and must conclude by December 2025.

Eligible applicants include professional schools, healthcare institutions, medical societies, and organizations with a mission in healthcare education or improvement. Projects must be led by an accredited organization if they provide continuing education credit. Pfizer will consider funding up to $300,000 per project, with 1-2 projects expected to be awarded. Funds may include direct and indirect costs (capped at 28%).

Applications should focus on clinical and educational priorities, such as severity assessment, treatment optimization, and the long-term risk-benefit analysis of therapies for AD and AA. Submissions must include a project proposal addressing goals, audience, innovation, methods, anticipated outcomes, dissemination plans, and a detailed budget. Overhead costs must align with Pfizer’s guidelines, and funds cannot support therapeutic asset purchases.

Interested organizations can apply through Pfizer’s CyberGrants portal, adhering to specified submission requirements. Pfizer encourages applicants to confirm their eligibility to receive funding and consult legal or institutional counsel on grant terms. For assistance, applicants can contact Pfizer’s Grant Officer. This program emphasizes advancing dermatology education and improving patient outcomes through innovative and impactful projects.